MiNK Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MiNK Therapeutics reported initial Day 28 observations from its randomized Phase 2 trial (C-1300-02) of agenT-797 in acute lung injury in Ukraine: treated patients showed improved oxygenation, infection control, ventilator/vasopressor liberation, reduced inflammatory markers, and no major serious adverse events attributed to the drug. The company established a paid named-patient access program in Brazil through Orphan Drug Consulting, enabling per-patient physician requests for agenT-797 under Brazilian regulatory authorization, generating per-patient revenue. Cash position declined to $8.8M (June 30, 2026) from $13.4M (December 31, 2025); Q2 2026 net loss was $3.1M ($0.62/share).
Why this rating
Early Phase 2 lung injury data without major safety signals and revenue-generating access program are meaningful for $10.9M market-cap company. Cash burn ($3.1M/quarter) is material relative to $8.8M cash. U.S. trial expansion underway; runway limited.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.